Summary
Aims To propose a method to help the clinical doctors to estimate the patients’ probability of suffering transfusion reaction during or after the transfusion treatment.
Background Blood components could be regarded as drugs that may cause adverse reactions while the transfusion is a kind of therapeutic procedure. The incidence of adverse transfusion reaction (ATR) is about 2‰, so some ATR might be neglected by clinical doctors. The ATR may affects patients’prognosis and even causes life threatening problems if not treated quickly and effectively. So, it is necessary to assess the patients’risk of ATR before transfusion and it is very important for ATRs’prevention and management.
Methods/materials The 79 hospitals reported ATR covered most of the mainland in China except Xizang province. From May 2018 to June 2019, there were about 1500 ATR cases. By Apriori algorithm and complex network method, information of these cases were extracted. The diseases which most probable encounter transfusion reactions after transfusion were screened out and it would be possible to estimate the probability of transfusion reaction of the disease that needs transfusion treatment.
Results Even though the average incidence of ATR is about 2‰, i.e. on the order of 10−3, for cancer patients the incidence of transfusion reaction is at least on the order of 10−2. And diseases of blood and hematopoietic organs, partus and puerperium, the incidence of transfusion reaction might be higher than the order of 10−3. The gastrointestinal hemorrhage patients need repeated transfusion, however their incidence of ATR might be around the order of 10−3. This means that even though we have thought the history of transfusion might increase the incidence of ATR, it does not increase the incidence significantly.
Conclusion The incidence of ATR in different groups of patients are different. For instance, in the 0-19 age group, cancer patients transfused by platelet the incidence is higher than 1% much higher than the average incidence. The ATR incidence among the gastrointestinal hemorrhage patients transfused by plasma is higher than 0.9‰. And most of the patients in this group also have the history of transfusion. So the transfusion history might increase the ATR incidence, however, it depends on the patients’ condition, including the disease they are suffering. Evaluating the patients’ condition before transfusion is important. In this study we have proposed a method to valuate the patients’ condition before transfusion. Clinical doctors might use the method to estimate the detailed incidence of ATR in their hospital. This might be helpful to prevent the ATR to some extent.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by was supported by Fundamental Research Funds for the Central Universities (Grants:3332019170). Availability of the "Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (Grants:2018PT32016)"
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data in the manuscript are supplied by the Key laboratory of transfusion adverse reactions Chinese academy of medical science and Peking union medical college